drugset
drugset / Trial / NCT03380871

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

NCT03380871 ↗

Phase 1 Completed 38 enrolled BioNTech US Inc. Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if treatment with NEO-PV-01 in combination with pembrolizumab and chemotherapy (pembrolizumab/chemotherapy) is safe and useful for patients with lung cancer. The study also will assess if the NEO-PV-01 vaccine, when given together with pembrolizumab and chemotherapy, can improve your response compared with pembrolizumab and chemotherapy treatment alone. All eligible patients will receive NEO-PV-01 + Adjuvant, pembrolizumab and chemotherapy while on this trial.

Timeline

Start
2018-05-04
Primary completion
2019-10-31
Completion
2021-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown —
Subject NEO-PV-01 Vaccine — Subcutaneous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 —

Indications

non-small cell lung carcinoma